JP7449583B2 - 標的特異的複合体及びその用途 - Google Patents

標的特異的複合体及びその用途 Download PDF

Info

Publication number
JP7449583B2
JP7449583B2 JP2021504091A JP2021504091A JP7449583B2 JP 7449583 B2 JP7449583 B2 JP 7449583B2 JP 2021504091 A JP2021504091 A JP 2021504091A JP 2021504091 A JP2021504091 A JP 2021504091A JP 7449583 B2 JP7449583 B2 JP 7449583B2
Authority
JP
Japan
Prior art keywords
cancer
target
cells
infrared light
specific complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021504091A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020179749A1 (https=
Inventor
和秀 佐藤
一臣 高橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokai National Higher Education and Research System NUC
Original Assignee
Tokai National Higher Education and Research System NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokai National Higher Education and Research System NUC filed Critical Tokai National Higher Education and Research System NUC
Publication of JPWO2020179749A1 publication Critical patent/JPWO2020179749A1/ja
Application granted granted Critical
Publication of JP7449583B2 publication Critical patent/JP7449583B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021504091A 2019-03-05 2020-03-02 標的特異的複合体及びその用途 Active JP7449583B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019039986 2019-03-05
JP2019039986 2019-03-05
PCT/JP2020/008751 WO2020179749A1 (ja) 2019-03-05 2020-03-02 標的特異的複合体及びその用途

Publications (2)

Publication Number Publication Date
JPWO2020179749A1 JPWO2020179749A1 (https=) 2020-09-10
JP7449583B2 true JP7449583B2 (ja) 2024-03-14

Family

ID=72338127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021504091A Active JP7449583B2 (ja) 2019-03-05 2020-03-02 標的特異的複合体及びその用途

Country Status (3)

Country Link
US (1) US20220257765A1 (https=)
JP (1) JP7449583B2 (https=)
WO (1) WO2020179749A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022050376A1 (https=) * 2020-09-04 2022-03-10

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022107573A1 (https=) 2020-11-17 2022-05-27
WO2023026791A1 (ja) 2021-08-27 2023-03-02 株式会社免疫生物研究所 ｃ－ＫＩＴ陽性腫瘍特異的抗体断片
CN115504984B (zh) * 2022-09-09 2023-07-25 南京诺源医疗器械有限公司 一种靶向α型叶酸受体的培美近红外荧光分子及其制备方法和应用
CN117159711A (zh) * 2023-08-01 2023-12-05 中国科学院基础医学与肿瘤研究所(筹) 一种抗体偶联物及其制备方法和在制备近红外光免疫疗法用药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031448A1 (en) 2016-08-11 2018-02-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near-ir light-cleavable conjugates and conjugate precursors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031448A1 (en) 2016-08-11 2018-02-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near-ir light-cleavable conjugates and conjugate precursors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SATO, K., et al，Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies:，ACS Cent. Sci.，2018年，Vol. 4，pp. 1559-1569
TSAI, Y., et al，Targeted Delivery of Functionalized Upconversion Nanoparticles for Externally Triggered Photothermal，Theranostics，2018年，Vol. 8, No. 5，pp. 1435-1448
小林久隆，特異性を重視した新たな癌の分子イメージングと近赤外光線免疫療法，Drug Delivery System，2014年，Vol. 29, No. 4，pp. 274-284

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022050376A1 (https=) * 2020-09-04 2022-03-10
JP7839553B2 (ja) 2020-09-04 2026-04-02 国立大学法人東海国立大学機構 光を用いた薬物伝送方法、及び標的集積型複合体

Also Published As

Publication number Publication date
WO2020179749A1 (ja) 2020-09-10
JPWO2020179749A1 (https=) 2020-09-10
US20220257765A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
JP7449583B2 (ja) 標的特異的複合体及びその用途
JP7458981B2 (ja) 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
TWI862473B (zh) 抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
Mack et al. The next generation of antibody drug conjugates
Chu et al. Anti-CD20 multivalent HPMA copolymer-Fab′ conjugates for the direct induction of apoptosis
US20070190060A1 (en) Passive targeting of cytotoxic agents
JP2020525542A (ja) Ｒｏｒ１抗体免疫複合体
JP7769032B2 (ja) 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
US20190290775A1 (en) Use of Antibody Drug Conjugates Comprising Tubulin Disrupting Agents to Treat Solid Tumor
JP7177131B2 (ja) アポトーシスを誘導するための組成物及び方法
TW201718021A (zh) 包含金屬奈米粒子、連接物及抗體之複合物
JP2024505556A (ja) がん、腫瘍および腫瘍細胞の局所および全身処置のための方法
Lidický et al. Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab
JP7614690B1 (ja) 腫瘍微小環境をターゲットとする光免疫療法に用いる医薬組成物、治療効果確認のためのマーカー、及び検査方法
CN114173822B (zh) 用胶原结合药物载体治疗癌症的方法和组合物
WO2024219442A1 (ja) 抗体－薬物コンジュゲートと他の薬剤との組み合わせ
WO2023048231A1 (ja) 腫瘍細胞を死滅させるための医薬
KR20220064293A (ko) 표적 치료제의 치료 효과 증진을 위한 항체 기반 컨쥬게이트
Gutbrodt Armed vascular targeting antibodies for the treatment of acute myeloid leukemia
TW202440169A (zh) 抗體-藥物結合物與dnmt抑制劑之組合
WO2024210162A1 (ja) 抗ｍｕｃ１抗体－薬物コンジュゲート投与による薬剤低感受性がんの治療方法
WO2023190827A1 (ja) ｐＨ依存性抗硫酸化グリコサミノグリカン抗体及び抗体薬物複合体
WO2024034684A1 (ja) 新薬物複合体
KR20250058747A (ko) 인간화 항 pvr 항체의 약물 접합체
KR20250108097A (ko) Egfr을 표적으로 하는 항체-약물 접합체를 이용한 비인두암 치료

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240226

R150 Certificate of patent or registration of utility model

Ref document number: 7449583

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150